Autonomix Medical, Inc. (NASDAQ: AMIX) Reviews Positive Results Seen in Pancreatic Cancer Pain Trial in Virtual Investor “What This Means” Segment
03 Luglio 2024 - 3:00PM
Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the
“Company”), a medical device company focused on advancing
innovative technologies to revolutionize how diseases involving the
nervous system are diagnosed and treated, today announced that it
recently participated in a Virtual Investor “What This Means”
segment.
For the segment, Dr. Robert Schwartz, Chief
Medical Officer of Autonomix, discussed the current standard of
care for people with pancreatic cancer pain and how Autonomix is
working to significantly advance pain management and allow for more
effective intervention with fewer side effects that can improve
quality of life for these patients. Additionally, Dr. Schwartz
highlighted some key takeaways from the preliminary positive
results from the first five “lead-in” patients in the Company’s
ongoing proof-of-concept (PoC) human clinical trial and what this
means for the Company, for patients, and for the Autonomix
technology moving forward.
The “What This Means” segment can be accessed
here.
The Company recently announced preliminary
positive results from the first five “lead-in” patients in the
Company’s ongoing PoC human clinical trial evaluating the safety
and effectiveness of delivering transvascular energy to ablate
relevant problematic nerves and mitigate pain in patients with
pancreatic cancer pain and highlighted patient testimonials from
some of the trial participants and treating physician. Click here
to watch the testimonials.
About Autonomix Medical,
Inc.
Autonomix is a medical device company focused on
advancing innovative technologies to revolutionize how diseases
involving the nervous system are diagnosed and treated. The
Company’s first-in-class technology platform includes a
catheter-based microchip sensing array that has the ability to
detect and differentiate neural signals with approximately 3,000
times greater sensitivity than currently available technologies. We
believe this will enable, for the first time ever, transvascular
diagnosis and treatment of diseases involving the peripheral
nervous system virtually anywhere in the body.
We are initially developing technology for the
treatment of pain, with initial trials focused on pancreatic
cancer, a condition that causes debilitating pain and is without an
effective solution. Our technology constitutes a platform to
address dozens of indications, including cardiology, hypertension
and chronic pain management, across a wide disease spectrum. Our
technology is investigational and has not yet been cleared for
marketing in the United States.
For more information, visit autonomix.com and
connect with the Company on X, LinkedIn, Instagram and
Facebook.
Forward Looking Statements
Some of the statements in this release are
“forward-looking statements,” which involve risks and
uncertainties. Forward-looking statements in this press release
include, without limitation, the potential of the technology to
treat pain associated with pancreatic cancer, to successfully
enroll patients within the specific timeframe, and to complete its
clinical study in pancreatic cancer pain. Such forward-looking
statements can be identified by the use of words such as “should,”
“might,” “may,” “intends,” “anticipates,” “believes,” “estimates,”
“projects,” “forecasts,” “expects,” “plans,” and “proposes.”
Although Autonomix believes that the
expectations reflected in these forward-looking statements are
based on reasonable assumptions, there are a number of risks and
uncertainties that could cause actual results to differ materially
from such forward-looking statements. You are urged to carefully
review and consider any cautionary statements and other
disclosures, including the statements made under the heading “Risk
Factors” and elsewhere in the Annual Report on Form 10-K filed with
the U.S. Securities and Exchange Commission (SEC) on May 31, 2024.
Forward-looking statements speak only as of the date of the
document in which they are contained and Autonomix does not
undertake any duty to update any forward-looking statements except
as may be required by law.
Investor and Media Contact
JTC Team, LLCJenene Thomas
833-475-8247autonomix@jtcir.com
Grafico Azioni Autonomix Medical (NASDAQ:AMIX)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Autonomix Medical (NASDAQ:AMIX)
Storico
Da Dic 2023 a Dic 2024